AAPP 2025 industry supported symposia (continuing education) and showcases (non-continuing education) are programs developed for educational purposes. All industry-supported programming at AAPP 2025 is designed for the psychiatric pharmacist and is included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation, and each one provides 1.0 contact hours of ACPE credit.

Attendees! A few reminders:

• Your badge may be scanned upon entry capturing name, credentials, city, state only
• We appreciate you keeping noise to a minimum
• All events are live-streamed and recorded
• Fill the room front to back
• Do not sit at tables with reserved signs
• All industry events feature a meal or refreshment break served 15 minutes before the session start time in Salt Lake CD-L2
• Meals are limited and will be served at tables only
• A limited number of vegetarian/vegan/gluten free meals are available. If desired, please inform the server upon taking a seat
• Plates will not be removed after programming starts to minimize noise

Monday, April 28, 8:15 AM - 9:15 AM (CDT)

Breakfast will be served from 7:00-7:15 AM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Sniffing Out the Truth: Strategies for the Effective Recognition and Management When A “Whiff of Mania” is Present in Patients With Depression

Learning Objectives

1. Recognize the impact of mixed features on quality of life, treatment selection, and outcomes for patients with depression.
2. Collaborate with patients, loved ones, and the care team to improve the early and accurate diagnosis of depressive mixed states (DMX).
3. Implement evidence-based treatments for DMX and reduce the use of potentially harmful treatment strategies.

Faculty: Joseph F. Goldberg, MD

Supported by

Monday, April 28, 12:30 PM (CDT)

Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Names Will Never Hurt Me? “Antipsychotics” in the Treatment of Mood Disorders

Learning Objectives

1. Appreciate the consequences of our current psychotropic nomenclature to optimal management and outcomes of mood disorders.
2. Evaluate the many approvals and evidence-based uses of serotonin dopamine antagonists/partial agonists (SDA-PAs) in the treatment of mood disorders.
3. Collaborate with patients and members of the care team to integrate SDA-PAs into the treatment of mood disorders in a way that optimizes acceptance,
   adherence, and outcomes.
4. Advocate for the widespread adoption of more appropriate and useful psychotropic nomenclature.

Faculty: Joseph F. Goldberg, MD

Supported by

This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.

Sunday, April 27, 12:30 PM (CDT)

Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.

Monday, April 28, 5:45 PM - 6:45 PM (CDT)

Break refreshments will be served from 4:30-4:45 PM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Clozapine RE(MS)defined: Enhancing Psychiatric Pharmacy Practice with Therapeutic Drug Monitoring and Updated Guidelines

Overview: This workshop will explore the pending changes in Clozapine REMS, providing psychiatric pharmacists with essential knowledge on the appropriate use of clozapine and the critical role of the therapeutic drug monitoring (TDM) in optimizing patient outcomes. Participants will gain practical insights into navigating regulatory updates and enhancing clinical decision-making. 

Learning Objectives

1. Explain the pending changes in the Clozapine REMS program and their implications of psychiatric pharmacy practice.
2. Identify clinical scenarios where clozapine is the preferred treatment and describe its unique role in managing treatment-resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia. 
3. Discuss the importance of TDM in clozapine therapy, its rapid results, and how to interpret levels and adjust dosages to optimize efficacy and safety.
4. Develop strategies to integrate updated REMS requirements and TDM protocols into pharmacy workflows to ensure compliance and improve patient care.
5. Evaluate case studies to illustrate how the use of clozapine, informed by TDM, leads to better therapeutic outcomes for patients with complex psychiatric needs. 

Supported by

This activity is supported by Saladax Biomedical, Inc.

Tuesday, April 29, 8:15 AM - 9:15 AM (CDT)

Breakfast will be served from 7:00-7:15 AM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Learn About COBENFY (xanomeline and trospium chloride): Where Does It Fit in Your Practice?

Overview: Don't miss this opportunity to learn about COBENFY as a treatment option for your patients. Explore COBENFY's clinical profile, including efficacy, safety, and dosing information. This program also highlights practical considerations when prescribing COBENFY.

Learning Objectives

1. Explore the persistent challenges and evolving understanding of schizophrenia.
2. Review the short- and long-term data supporting the efficacy, safety and tolerability profile of COBENFY.
3. Review practical considerations when prescribing COBENFY.

Faculty

Alberto Augsten, PharmD, MS, BCPP, DABAT Pharmacy Clinical Manager, Long-Acting Therapy Clinic (LAT) Manager, PGY2 Psychiatric Pharmacy Residency Director, Board Certified Clinical Toxicologist Memorial Regional Hospital Hollywood, FL

 

Supported by

This activity is supported by Bristol Myers Squibb

 

Tuesday, April 29, 12:30 PM - 1:30 PM (CDT)

Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

TechTonic Shift: Prescription Digital Therapeutics and the Future of Psychiatric Pharmacy

Overview: Discover the transformative potential of prescription digital therapeutics (PDTs), including a deep dive into the evidence supporting these technologies as effective treatments for patients with serious mental illnesses. In this industry showcase, distinguished faculty with expertise in the development and implementation of digital technologies into healthcare systems will discuss the evaluation of digital therapies in clinical trials and real-world studies in mental health conditions and how they may be implemented into practice.

Learning Objectives

1. Review the challenges and unmet needs experienced by psychiatric pharmacists in the delivery of mental health care including potential solutions.
2. Educate on digital therapeutic research from early phase investigational studies, registrational trials, and real-world evidence in mental illness.
3. Explore the role of psychiatric pharmacists in the implementation and utilization of digital therapeutics into treatment of mental health disorders.

Faculty

	Kari Franson, PharmD, PhD, BCPP Senior Associate Dean for Academic and Student Affairs & Professor of Clinical Pharmacy Titus Family Department of Clinical Pharmacy USC Mann School of Pharmacy & Pharmaceutical Sciences
	Lisa Marsch, PhD Director for the Dartmouth Center for Technology and Behavioral Health (CTBH) Andrew G. Wallace Professor within the Departments of Psychiatry and Biomedical Data Science Geisel School of Medicine at Dartmouth College
	Nathaniel Rickles, PharmD, PhD, BCPP Associate Dean of Admissions and Student Affairs Professor of Pharmacy Practice Institute for Collaboration on Health, Intervention, and Policy (InCHIP) at the University of Connecticut

 

Supported by

This activity is supported by Boehringer Ingelheim